Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis

• Published in: World journal of gastroenterology : WJG Vol. 27; no. 22; pp. 3050 - 3063
• Main Authors: Moran, Segundo, López-Sánchez, Marlene, Milke-García, María del Pilar, Rodríguez-Leal, Gustavo
• Format: Journal Article
• Language: English
• Published: Baishideng Publishing Group Inc 14.06.2021
• Subjects: Minireviews
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v27.i22.3050

Minimal hepatic encephalopathy (MHE) corresponds to the earliest stage of hepatic encephalopathy (HE). MHE does not present clinically detectable neurological-psychiatric abnormalities but is characterized by imperceptible neurocognitive alterations detected during routine clinical examination via neuropsychological or psychometrical tests. MHE may affect daily activities and reduce job performance and quality of life. MHE can increase the risk of accidents and may develop into overt encephalopathy, worsening the prognosis of patients with liver cirrhosis. Despite a lack of consensus on the therapeutic indication, interest in finding novel strategies for prevention or reversion has led to numerous clinical trials; their results are the main objective of this review. Many studies address the treatment of MHE, which is mainly based on the strategies and previous management of overt HE. Current alternatives for the management of MHE include measures to maintain nutritional status while avoiding sarcopenia, and manipulation of intestinal microbiota with non-absorbable disaccharides such as lactulose, antibiotics such as rifaximin, and administration of different probiotics. This review analyzes the results of clinical studies that evaluated the effects of different treatments for MHE.